PTO/SB/08a (04-07)

Approved for use through 09/30/2007 OMB 0851-0031

U.S. Patent and Trademark Office. U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO			ot or 1990, no persons are	Complete if Known			
INIE	ODMATION DIS	201	OSLIDE	Application Number	10/686,907	Confirmation No.: 7509	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Filing Date	October 17, 2003		
				First Named Inventor	Piero DEL SOLDATO et al.		
Form PTO/SB/08a (Use as many sheets as necessary)			Art Unit	1617			
			Examiner Name	Yong SOO CH	ONG		
Sheet	1	of	2	Attorney Docket Number	026220-00039		

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Initials*	No.1	Number-Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	
		US- 5,859,053 A	01-12-1999	Eva Lesur et al.		
		US- 5,861,426 A	01-19-1999	Piero Del Soldato et al		
		US- 6,040,341 A	03-21-2000	Piero Del Soldato et al.		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		IIS.			-	

## FOREIGN PATENT DOCUMENTS

	,		JOH TAILIN	DOCUMENTS		emperature o
Examiner Initials*	Cite No.	Foreign Patent Document  Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant	T
					Figures Appear	
		EP 0 722 434 B1	07-29-1998	NICOX S.A.		X
		EP 0 738 706 A1	10-23-1996	PRODES, S.A.		X
		WO 98/09948 A2	03-12-1998	NICOX S.A		X
		WO 00/51988 A1	09-08-2000	NICOX S.A		X
		WO 00/61537 A2	10-19-2000	NICOX S.A.		X
		WO 01/12584 A2	02-22-2001	NICOX S.A.		X
	-					
	+		-			+-
						+
						+

Signature	Considered	
	if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.	

"E-Adminstre. Initial intervence considered, whether or hot classics is in contromance with where you. Links when my many classics in not in contromance and and a classics of the control in the intervence of the classics of the control in the intervence of USPTO Patent Documents at www.uspig.gov or WPEP 901.04. "Enter Office that Issued the document, by the two-letter code (WPEO Standard ST.3)." For Japanese patent document, his many classics of the part of the Emperor must precede the serial number of the perfect document. Which of document by the parproprise symbol and an ancidated on the occument under WIPO Standard ST.10 if possible. "Applicant is to place a check mark here if English language translation is attached. AB indicates that only on English language states data table."

This collection of information is required by 37 CFR 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 38 U.S. (1.2 and 30 CFR 1.14. This collection is estimated to take 2 hours to complete, incuding pathing preparing, and submitting the completed application form to the USPTO. The will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this budnet, should be sent to the Chief information Officiar. U.S. Patent and Transferred Cffice, U.S. Patent and Tra

PTO/SB/085 (04-07)

Approved for use through 09/30/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449B/PTO

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
Form PTO/SB/08b

(Use as many sheets as necessary)

of

Sheet

Complete if Known Application Number 10/686.907 Confirmation No.: 7509 October 17, 2003 Filing Date First Named Inventor Piero DEL SOLDATO et al. Art Unit 1617 Examiner Name Yong SOO CHONG Attorney Docket Number 026220-00039

NON PATENT LITERATURE DOCUMENTS  Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the adjust when appropriate in title of the item (hook, managing, injuried, senal, supposed in						
Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, senal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²				
	O. A. AL-SWAYEH et al., "Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity", British Journal of Pharmacology (2000) 130, pp. 1453-1456.					
	Adrian W. BAK et al., "CYCLOOXYGENASE-INDEPENDENT CHEMOPREVENTION WITH AN ASPIRIN DERIVATIVE IN A RAT MODEL OF COLONIC ADENOCARCINOMA", Life Sciences, Vol. 62, No. 23, 1998, pp. PL 367-373					
	Viviane BERTRAND et al., 'Role of tumour necrosis factor-o and inducible nitric oxide synthase in the prevention of nitro- flurbiprofen small intestine toxicity', European Journal of Pharmacology 356 (1998), pp. 245-253					
	Gary L. WENK et al., "Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons", European Journal of Pharmacology 402 (2000), pp. 77-85.					
	Richard J. BING et al., "The Pharmacology of a New Nitric Oxide Doner: B-NOD", Biochemical and Biophysical Research Communications 275, (2000), pp. 350-353.					
	Cite No.1	Dre  Include rearrie of the author (in CAPITAL LETTERS), tills of the article (when approximately the first rearries of the author (in CAPITAL LETTERS), tills of the article (when approximately the control of the published.  O. A. AL-SWAYEH et al., "Nitroparacetamol exhibits anti-inflammatory and anti-nociceptive activity", British Journal of Pharmacology (2000) 130, pp. 1453-1456.  Adrian W. BAK et al., "CYCLOOXYGENASE-INDEPENDENT CHEMOPREVENTION WITH AN ASPIRIN DERIVATIVE IN A RATI MODEL OF COLONIC ADENOCARCINOMA", Life Sciences, Vol. 62, No. 23, 1998, pp. PL 367-373  Viviane BERTRAND et al., "Role of tumour necrosis factor-or and induction nitric oxide synthase in the prevention of nitro-fluribriprofen small intestine toxicity", European Journal of Pharmacology 356 (1998), pp. 245-253  Gary L. WENK et al., "Mechanisms to prevent the toxicity of chronic neuroniflammation on forebrain cholinergic neurons", European Journal of Pharmacology 402 (2000), pp. 77-65.  Richard J. BING et al., "The Pharmacology of a New Nitric Oxide Doner: B-NOD", Biochemical and Blophysical Research.				

Examiner	Date
Signature	Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional) Applicant is to place a check mark here if English language Translation is attached

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 114. This collection is estimated to take 2 hours to complete, including gathering preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.